PDCD1 and neoplasm: Since ZSTK474 treatment alone were not able to completely eradicate the initial CMS5a-NY-ESO-1 tumor, mice that had completely eradicated the initial tumor by treatment with anti-PD-1 mAb with or without ZSTK474 were rechallenged with CMS5a-NY-ESO-1 cells (right hind flank) and parental CMS5a cells (left hind flank) 70 days after primary tumor inoculation.